gboin

This paper proposes the generalized Bayesian optimal interval design for dose-finding accounting for efficacy and toxicity grades. The new design, named "gBOIN-ET" design, is model-assisted, simple, and straightforward to implement in actual oncology dose-finding trials than model-based approaches. 'TITEgBOIN' provides the set up and calculations needed to run a dose-finding trial using bayesian optimal interval (BOIN) (Yuan et al. (2016) doi:10.1158/1078-0432.CCR-16-0592), generalized bayesian optimal interval (gBOIN) (Mu et al. (2019) doi:10.1111/rssc.12263), time-to-event bayesian optimal interval (TITEBOIN) (Lin et al. (2020) doi ... We show that gBOIN has the desirable finite property of coherence and the large sample property of consistency. Numerical studies show that gBOIN, albeit simplistic, often outperforms some existing, more complicated model-based designs. This paper proposes the generalized Bayesian optimal interval design for dose-finding accounting for efficacy and toxicity grades. The new design, named “gBOIN-ET” design, is model-assisted, simple, and straightforward to implement in actual oncology dose-finding trials than model-based approaches. The gBOIN-ET design is a phase I/II model-assisted, non-parametric design that is an extension of the BOIN-ET design and that accounts for ordinal graded efficacy and toxicity. gBOIN-ET is simple and easy to implement in oncology trials than model-based approaches. gBOIN‐ET: The generalized Bayesian optimal interval design for optimal dose‐finding accounting for ordinal graded efficacy and toxicity in early clinical trials. Biometrical Journal. The default is alpha1=0.5. for Bayesian optimal in-terval (BOIN)/Generalized Bayesian optimal interval (gBOIN), "NA" should be assigned. for Time-to-event bayesian optimal interval (TITEBOIN)/Time-to-event gener-alized bayesian optimal interval (TITEgBOIN), a number from (0,1) that assume toxicity outcomes occurred with probability alpha1 in ... The gBOIN design is a more general version of the BOIN design that can handle continuous, quasi-binary, and binary toxicity endpoints. The gBOIN design has good statistical operating characteristics compared to existing designs that handle toxicity grades such as the quasi-CRM design . It is simple to implement, since its dosing decisions ... A simulation study shows that the TITE-gBOIN design has a higher probability of selecting the MTDs correctly and allocating more patients to the MTDs across various realistic settings while ... Mu R, Zongliang H, Guoying X, Pan H, et al. An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials. BMC Med Res Methodol. 2021;21(1):1–12. Article Google Scholar Liu S, Yuan Y. Bayesian optimal interval designs for phase I clinical trials. J R Stat Soc: Ser C: Appl Stat. 2015;64(3):507–23. The relationships of operating characteristics and sample sizes of gBOIN and gBOINS when the target toxicity rates are 20% and 30%. The two pictures on the left panel, only one dose lying inside ... The proposed design, named "TITE-gBOIN" design, is a nonparametric and model-assisted design and has the virtues of robustness, simplicity and straightforward to implement in actual oncology dose-finding trials. A simulation study shows that the TITE-gBOIN design has a higher probability of selecting the MTDs correctly and allocating more ...